Search hospitals > South Carolina > Myrtle Beach

Carolina Urologic Research Center

Claim this profile
Myrtle Beach, South Carolina 29572
Global Leader in Prostate Cancer
Global Leader in Bladder Cancer
Conducts research for Transitional Cell Carcinoma
Conducts research for Cancer
Conducts research for Vulval Intraepithelial Neoplasia
158 reported clinical trials
3 medical researchers
Photo of Carolina Urologic Research Center in Myrtle BeachPhoto of Carolina Urologic Research Center in Myrtle BeachPhoto of Carolina Urologic Research Center in Myrtle Beach

Summary

Carolina Urologic Research Center is a medical facility located in Myrtle Beach, South Carolina. This center is recognized for care of Prostate Cancer, Bladder Cancer, Transitional Cell Carcinoma, Cancer, Vulval Intraepithelial Neoplasia and other specialties. Carolina Urologic Research Center is involved with conducting 158 clinical trials across 99 conditions. There are 3 research doctors associated with this hospital, such as Neal Shore, Abhishek Srivastava, MD, and Robert Jansen, MD.

Area of expertise

1Prostate Cancer
Global Leader
Carolina Urologic Research Center has run 111 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II
2Bladder Cancer
Global Leader
Carolina Urologic Research Center has run 50 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III
FGFR3 positive

Top PIs

Clinical Trials running at Carolina Urologic Research Center

Prostate Cancer
Bladder Cancer
Kidney Cancer
Ovarian Cancer
Lung Cancer
Cervical Adenocarcinoma
Transitional Cell Carcinoma
Relapse
Squamous Cell Carcinoma
Ureter Cancer
Image of trial facility.

Lutetium (177Lu) Vipivotide Tetraxetan

for Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Recruiting2 awards Phase 36 criteria
Image of trial facility.

64Cu-SAR-bisPSMA PET Scan

for Prostate Cancer

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

AAA817 + ARPI

for Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.
Recruiting2 awards Phase 37 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Carolina Urologic Research Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security